STX-100
- Generic Name
- STX-100
- Drug Type
- Biotech
- CAS Number
- 1439902-67-6
- Unique Ingredient Identifier
- JD43Y6YF3N
- Background
STX-100 is under investigation in clinical trial NCT01371305 (STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)).
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 109
- Registration Number
- NCT03573505
- Locations
- 🇬🇧
Research Site, Leeds, West Yorkshire, United Kingdom
🇺🇸Reserach Site, Houston, Texas, United States
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Phase 2
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 41
- Registration Number
- NCT01371305
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath